Gern­gross’ Adimab hands over RSV an­ti­bod­ies to Ar­sa­nis, a biotech he co-found­ed in Vi­en­na

Till­man Gern­gross is tak­ing a group of an­ti­bod­ies iden­ti­fied by his dis­cov­ery group Adimab and hand­ing them over to Ar­sa­nis, a Vi­en­na-based biotech he co-found­ed to de­vel­op some of the pro­grams he has set up at the moth­er ship in Lebanon, NH. And the biotech has a $9.3 mil­lion grant from the Bill & Melin­da Gates Foun­da­tion to get the work through IND-en­abling stud­ies.

The tar­get this time is RSV, or res­pi­ra­to­ry syn­cy­tial virus, which in­fects the res­pi­ra­to­ry sys­tem.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.